Cargando…

Differential Impacts of Endogenous Antioxidants on Clinical Symptoms and Cognitive Function in Acute and Chronic Schizophrenia Patients

BACKGROUND: Impaired antioxidant defense is implicated in the pathophysiology of schizophrenia, and superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) are 3 first-line endogenous antioxidants. Various cognitive functions decline differently during the schizophrenia course. The charact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chieh-Hsin, Li, Tin-May, Huang, Yu-Jhen, Chen, Shaw-Ji, Lane, Hsien-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Regular Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464923/ https://www.ncbi.nlm.nih.gov/pubmed/37422918 http://dx.doi.org/10.1093/ijnp/pyad040

Ejemplares similares

Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease
por: Lane, Hsien‐Yuan, et al.
Publicado: (2022)

Polymorphism in the LASP1 gene promoter region alters cognitive functions of patients with schizophrenia
por: Lin, Chieh-Hsin, et al.
Publicado: (2019)

Blood D-Amino Acid Oxidase Levels Increased With Cognitive Decline Among People With Mild Cognitive Impairment: A Two-Year Prospective Study
por: Lin, Chieh-Hsin, et al.
Publicado: (2022)

Applying a bagging ensemble machine learning approach to predict functional outcome of schizophrenia with clinical symptoms and cognitive functions
por: Lin, Eugene, et al.
Publicado: (2021)

NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer’s Disease
por: Huang, Yu-Jhen, et al.
Publicado: (2012)

Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial
por: Lin, Chieh-Hsin, et al.
Publicado: (2022)

PICK1 Genetic Variation and Cognitive Function in Patients with Schizophrenia
por: Chen, Yi-Ting, et al.
Publicado: (2017)

Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease
por: Hsu, Wen-Yu, et al.
Publicado: (2018)

Combination of G72 Genetic Variation and G72 Protein Level to Detect Schizophrenia: Machine Learning Approaches
por: Lin, Eugene, et al.
Publicado: (2018)

Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial
por: Lane, Hsien-Yuan, et al.
Publicado: (2021)

Diagnosing Alzheimer’s Disease Specifically and Sensitively With pLG72 and Cystine/Glutamate Antiporter SLC7A11 AS Blood Biomarkers
por: Lane, Hsien-Yuan, et al.
Publicado: (2022)

Failure to mobilize cognitive control for challenging tasks correlates with symptom severity in schizophrenia
por: Baran, Bengi, et al.
Publicado: (2016)

C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia
por: Chang, Chun-Hung, et al.
Publicado: (2019)

Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia
por: Horne, Charlotte M., et al.
Publicado: (2021)

Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress
por: Lin, Chieh-Hsin, et al.
Publicado: (2019)

New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity
por: Huang, Yu-Jhen, et al.
Publicado: (2017)

Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment
por: Hung, Chung-Chieh, et al.
Publicado: (2021)

Loosening of Associations in Chronic Schizophrenia: Intersectionality of Verbal Learning, Negative Symptoms, and Brain Structure
por: Nestor, Paul G, et al.
Publicado: (2022)

Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences
por: Chen, Chien-Yu, et al.
Publicado: (2016)

d-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia
por: Cheng, Yu-Jung, et al.
Publicado: (2021)

Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study
por: Lin, Chieh-Hsin, et al.
Publicado: (2021)

Aberrant effective connectivity is associated with positive symptoms in first-episode schizophrenia
por: Dietz, Martin J., et al.
Publicado: (2020)

Prediction of functional outcomes of schizophrenia with genetic biomarkers using a bagging ensemble machine learning method with feature selection
por: Lin, Eugene, et al.
Publicado: (2021)

The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia
por: Lin, Chieh-Hsin, et al.
Publicado: (2019)

Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia
por: Lin, Chieh-Hsin, et al.
Publicado: (2019)

Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial
por: Lin, Chieh-Hsin, et al.
Publicado: (2021)

PM401. NMDA-enhancing agents improve cognitive function of patients with schizophrenia
por: Lane, Hsien-Yuan
Publicado: (2016)

Functional network changes and cognitive control in schizophrenia
por: Ray, Kimberly L., et al.
Publicado: (2017)

Cortico-cognition coupling in treatment resistant schizophrenia
por: Syeda, Warda T., et al.
Publicado: (2022)

Genetic Biomarkers on Age-Related Cognitive Decline
por: Lin, Chieh-Hsin, et al.
Publicado: (2017)

Attention to Irrelevant Cues Is Related to Positive Symptoms in Schizophrenia
por: Morris, Richard, et al.
Publicado: (2013)

Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
por: Davidson, Michael, et al.
Publicado: (2022)

PM405. Sodium Benzoate Add-on Treatment for Refractory Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Lin, Chieh-Hsin, et al.
Publicado: (2016)

A Network Approach to Trauma, Dissociative Symptoms, and Psychosis Symptoms in Schizophrenia Spectrum Disorders
por: Schlesselmann, Ante J, et al.
Publicado: (2022)

An Ensemble Approach to Predict Schizophrenia Using Protein Data in the N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways
por: Lin, Eugene, et al.
Publicado: (2020)

PM378. A reduced risk of severe hepatic outcome with paliperidone exposure in schizophrenia patients with viral hepatitis: a population-based retrospective cohort study
por: Chang, Chun-Hung, et al.
Publicado: (2016)

Evidence of Common Genetic Overlap Between Schizophrenia and Cognition
por: Hubbard, Leon, et al.
Publicado: (2016)

The Relationship Between Polygenic Risk Scores and Cognition in Schizophrenia
por: Richards, Alexander L, et al.
Publicado: (2020)

Brain morphological and functional features in cognitive subgroups of schizophrenia
por: Yasuda, Yuka, et al.
Publicado: (2019)

MEG resting-state oscillations and their relationship to clinical symptoms in schizophrenia
por: Zeev-Wolf, Maor, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ga5ffmcp0hlp3odo864v0lo74